AnaptysBio, Inc. ( NASDAQ:ANAB ) shareholders should be happy to see the share price up 13% in the last month. But ...

Fintel reports that on February 4, 2025, Wolfe Research initiated coverage of AnaptysBio (NasdaqGS:ANAB) with a Outperform ...

D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...

Vanda Pharmaceuticals and AnaptysBio have announced an exclusive worldwide licence agreement to develop and commercialise the ...

Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on Monday,RTT News reports. They ...

Wolfe Research analyst Andy Chen initiated coverage of AnaptysBio (ANAB) with an Outperform rating and $25 price target The stock’s current ...

Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...

SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that ...

Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.

Check the time stamp on this data. Updated AI-Generated Signals for Anaptysbio Inc. (ANAB) available here: ANAB. Type a few ...

Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat.com reports. Four ...